3 results
Approved WMOCompleted
The primary objective is to demonstrate non-inferiority of patients bilaterally implanted with the AcrySof® IQ ReSTOR® +2.5 D MIOL to AcrySof® IQ ReSTOR® +2.5 D MIOL in the dominant eye and AcrySof® IQ ReSTOR® +3.0 D in the fellow eye in binocular…
Approved WMOWill not start
This study will evaluate the safety, efficacy, and pharmacokinetics of UTTR1147A compared with placebo and compared with vedolizumab in patients with moderate to severe ulcerative colitis (UC).
Approved WMOCompleted
Primary: To demonstrate that high (100%) stimulation of ONS therapy reduces the mean attack frequency (MAF) in MICCH by at least 35% compared to low (30%) stimulation of ONS.Secondary: To evaluate • the rate of responders (>= 50% reduction in…